Key result
SARS-CoV-2 infection was not associated with altered serum levels of ACE2, angiotensin II, or aldosterone compared to symptomatic SARS-CoV-2 negative patients.
Why the study?
The role of the renin-angiotensin-aldosterone system (RAAS) in COVID-19 is controversially discussed, and RAAS activity may affect susceptibility to SARS-CoV-2 infection and patient outcomes.
Does SARS-CoV-2 infection alter serum levels of ACE2, angiotensin II, and aldosterone compared to patients with similar symptoms without COVID-19?
Population
24 SARS-CoV-2 positive and 61 SARS-CoV-2 negative patients presenting with similar symptoms in the emergency unit
Comparison
COVID-19 patients vs symptomatic control patients
Design
Prospective single-center study
Authors
Loading...
No RAAS marker differences at ED presentation in this cohort; leaves open effects in severe, hospitalized, or post-acute COVID-19.
Observational (n=85)
No
Does SARS-CoV-2 infection alter serum levels of ACE2, angiotensin II, and aldosterone compared to patients with similar symptoms without COVID-19?
SARS-CoV-2 infection does not appear to significantly alter systemic RAAS activity, including ACE2, angiotensin II, and aldosterone levels, at the time of emergency department presentation.
Rieder et al. (2020) conducted an observational in COVID-19 (n=85). SARS-CoV-2 infection vs. SARS-CoV-2 negative patients with similar symptoms was evaluated on Serum levels of ACE2, angiotensin II, and aldosterone. SARS-CoV-2 infection was not associated with altered serum levels of ACE2, angiotensin II, or aldosterone compared to symptomatic SARS-CoV-2 negative patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: